Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas.

针对SOX11的多克隆抗体不能鉴别套细胞淋巴瘤和其他B细胞非霍奇金淋巴瘤

Zhang LN,Cao X,Lu TX,Fan L,Wang L,Xu J,Zhang R,Zou ZJ,Wu JZ,Li JY,Xu W

阅读：432 American Journal of Clinical Pathology； 2013 December; 140 (6)

Abstract

To determine whether SOX11 is a diagnostic marker of mantle cell lymphoma (MCL).
We analyzed SOX11 expression in 349 B-cell non-Hodgkin lymphomas (B-NHLs) via immunohistochemistry.
Nuclear staining of SOX11 was observed in 54 (93.1%) of 58 MCLs. We noticed that SOX11 protein was also expressed on the nuclei in 8 (21.6%) of 37 B-lymphoblastic lymphomas, 45 (32.6%) of 138 diffuse large B-cell lymphomas, 15 (44.1%) of 34 follicular lymphomas, 8 (30.8%) of 26 Burkitt lymphomas, 2 (10.0%) of 20 chronic lymphocytic leukemia/small cell lymphomas, and 3 (18.8%) of 16 marginal zone lymphomas.
Although the positive rate of SOX11 expression in MCL was significantly higher than other B-NHLs (P < .001), polyclonal antibody targeting SOX11 is not able to identify MCL from B-NHLs because the nuclear staining of SOX11 was widely positive in B-NHLs.

摘要

为了明确SOX11能否用做套细胞淋巴瘤的诊断标记。
我们在349例B细胞性非霍奇金淋巴瘤中用免疫组化的方法分析SOX11的表达情况。在54/58（93.1%）的套细胞淋巴瘤病例中有SOX11核表达。我们同时注意到SOX11蛋白在8/37（21.6%）的B淋巴母细胞淋巴瘤、45/138（32.6%）的弥漫大B细胞淋巴瘤、15/34（44.1%）的滤泡淋巴瘤、8/26（30.8%）的伯基特淋巴瘤、2/20（10.0%）的慢性淋巴细胞白血病/小细胞淋巴瘤及3/16（18.8%）的边缘区淋巴瘤中有核表达。
尽管在套细胞淋巴瘤中SOX11的阳性表达率明显高于其他B细胞非霍奇金淋巴瘤（P<.001），但针对sox11的多克隆抗体不能用于鉴别套细胞淋巴瘤和其他b细胞性非霍奇金淋巴瘤，因为在多数b细胞性非霍奇金淋巴瘤中有sox11的核表达。

full text

我要评论

共0条评论

本文译者

hezejihong
译文：5 篇